咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Dendritic cell-based immunothe... 收藏

Dendritic cell-based immunotherapy for malignant glioma

Dendritic cell-based immunotherapy for malignant glioma

作     者:Jin-Hai GU Gang LI Jin-Hai GU;Gang LI

作者机构:Department of Neurosurgery Qilu Hospital of Shandong University Jinan 250012 China 

出 版 物:《Neuroscience Bulletin》 (神经科学通报(英文版))

年 卷 期:2008年第24卷第1期

页      面:39-44页

核心收录:

学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主  题:dendritic cell immunotherapy malignant glioma 

摘      要:The immunotherapy for malignant glioma faces unique difficult, due to some anatomical and immunological characteristics including the existence of blood brain barrier, the absence of lymphatic tissues and dendritic cells (DCs) in the central nervous system (CNS) parenchyma, and the presence of an immunosuppressive microenvironment. Therefore, immunothera-peutic approaches will not be beneficial unless the compromised immune status in malignant glioma patients is overcome. DC-based immunotherapy, vaccinating cancer patients with DCs pulsed with various tumor antigens, is one of the most promising immunotherapeutic approaches for treatment of malignantglioma because it seems able to overcome, at least partially, the immunosuppressive state associated with primary malignancies. The preparation of DCs, choice of antigen, and route and schedule of administration are improving and optimizing with rapid development of molecular biology and gene engineering technology. DC vaccination in humans, after a number of pre-clinical models and clinical trials, would increase the clinical benefits for malignant glioma immunotherapy.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分